Q3 2024 EPS Estimates for Karyopharm Therapeutics Inc. Lifted by Analyst (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright upped their Q3 2024 earnings estimates for Karyopharm Therapeutics in a note issued to investors on Wednesday, August 7th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.28) per share for the quarter, up from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.08) EPS, FY2025 earnings at ($0.96) EPS and FY2026 earnings at ($0.43) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $33.13 million during the quarter, compared to analyst estimates of $35.02 million.

A number of other research analysts have also recently issued reports on KPTI. Robert W. Baird cut their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday. StockNews.com raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.80.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock opened at $0.81 on Friday. The stock’s fifty day simple moving average is $0.93 and its 200 day simple moving average is $1.12. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The firm has a market cap of $100.94 million, a price-to-earnings ratio of -0.64 and a beta of 0.21.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC acquired a new position in Karyopharm Therapeutics during the fourth quarter valued at approximately $33,000. Simplicity Solutions LLC bought a new position in shares of Karyopharm Therapeutics during the fourth quarter worth $33,000. SG Americas Securities LLC grew its holdings in shares of Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock valued at $64,000 after buying an additional 54,839 shares during the period. Simplicity Wealth LLC bought a new stake in shares of Karyopharm Therapeutics in the 1st quarter valued at $66,000. Finally, Monashee Investment Management LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth $115,000. Institutional investors own 66.44% of the company’s stock.

Insiders Place Their Bets

In related news, Director Deepika Pakianathan sold 204,394 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $0.95, for a total value of $194,174.30. Following the transaction, the director now directly owns 14,697 shares in the company, valued at $13,962.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders sold 1,279,081 shares of company stock valued at $1,237,898. 4.30% of the stock is currently owned by insiders.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).